Literature DB >> 7568181

Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.

B A Faucheux1, N Nillesse, P Damier, G Spik, A Mouatt-Prigent, A Pierce, B Leveugle, N Kubis, J J Hauw, Y Agid.   

Abstract

The degeneration of nigral dopaminergic neurons in Parkinson disease is believed to be associated with oxidative stress. Since iron levels are increased in the substantia nigra of parkinsonian patients and this metal catalyzes the formation of free radicals, it may be involved in the mechanisms of nerve cell death. The cause of nigral iron increase is not understood. Iron acquisition by neurons may occur from iron-transferrin complexes with a direct interaction with specific membrane receptors, but recent results have shown a low density of transferrin receptors in the substantia nigra. To investigate whether neuronal death in Parkinson disease may be associated with changes in a pathway supplementary to that of transferrin, lactoferrin (lactotransferrin) receptor expression was studied in the mesencephalon. In this report we present evidence from immunohistochemical staining of postmortem human brain tissue that lactoferrin receptors are localized on neurons (perikarya, dendrites, axons), cerebral microvasculature, and, in some cases, glial cells. In parkinsonian patients, lactoferrin receptor immunoreactivity on neurons and microvessels was increased and more pronounced in those regions of the mesencephalon where the loss of dopaminergic neurons is severe. Moreover, in the substantia nigra, the intensity of immunoreactivity on neurons and microvessels was higher for patients with higher nigral dopaminergic loss. These data suggest that lactoferrin receptors on vulnerable neurons may increase intraneuronal iron levels and contribute to the degeneration of nigral dopaminergic neurons in Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568181      PMCID: PMC40850          DOI: 10.1073/pnas.92.21.9603

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study.

Authors:  P F Good; C W Olanow; D P Perl
Journal:  Brain Res       Date:  1992-10-16       Impact factor: 3.252

Review 2.  Are dopaminergic neurons selectively vulnerable to Parkinson's disease?

Authors:  Y Agid; M Ruberg; F Javoy-Agid; E Hirsch; R Raisman-Vozari; S Vyas; B Faucheux; P Michel; A Kastner; V Blanchard
Journal:  Adv Neurol       Date:  1993

3.  Immunolocalization of the lactotransferrin receptor on the human T lymphoblastic cell line Jurkat.

Authors:  B Y Bi; B Leveugle; J L Liu; A Collard; P Coppe; A C Roche; N Nillesse; M Capron; G Spik; J Mazurier
Journal:  Eur J Cell Biol       Date:  1994-10       Impact factor: 4.492

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease.

Authors:  A Kastner; E C Hirsch; Y Agid; F Javoy-Agid
Journal:  Brain Res       Date:  1993-03-26       Impact factor: 3.252

Review 6.  The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

Authors:  S Fahn; G Cohen
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

7.  Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.

Authors:  E C Hirsch; J P Brandel; P Galle; F Javoy-Agid; Y Agid
Journal:  J Neurochem       Date:  1991-02       Impact factor: 5.372

8.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

9.  Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol.

Authors:  K L Leenders; A Antonini; R Schwarzbach; P Smith-Jones; H Reist; D Ben-Shachar; M Youdim; V Henn
Journal:  J Neural Transm Suppl       Date:  1994

10.  Effect of intracellular iron depletion by picolinic acid on expression of the lactoferrin receptor in the human colon carcinoma cell subclone HT29-18-C1.

Authors:  T Mikogami; T Marianne; G Spik
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

View more
  33 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

Authors:  C Barcia; V Bautista; A Sánchez-Bahillo; E Fernández-Villalba; B Faucheux; M Poza y Poza; A Fernandez Barreiro; E C Hirsch; M-T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2005-01-24       Impact factor: 3.575

3.  Traceable microRNA-124 loaded nanoparticles as a new promising therapeutic tool for Parkinson's disease.

Authors:  Cláudia Saraiva; Lino Ferreira; Liliana Bernardino
Journal:  Neurogenesis (Austin)       Date:  2016-11-14

4.  Molecular mechanisms of non-transferrin-bound and transferring-bound iron uptake in primary hippocampal neurons.

Authors:  Changyi Ji; Daniel J Kosman
Journal:  J Neurochem       Date:  2015-03-10       Impact factor: 5.372

Review 5.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

Review 6.  Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment.

Authors:  B Halliwell
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 8.  Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  David Devos; Z Ioav Cabantchik; Caroline Moreau; Véronique Danel; Laura Mahoney-Sanchez; Hind Bouchaoui; Flore Gouel; Anne-Sophie Rolland; James A Duce; Jean-Christophe Devedjian
Journal:  J Neural Transm (Vienna)       Date:  2020-01-07       Impact factor: 3.575

Review 9.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

10.  Dendroaxonal transcytosis of transferrin in cultured hippocampal and sympathetic neurons.

Authors:  A Hémar; J C Olivo; E Williamson; R Saffrich; C G Dotti
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.